180 results about "Mesenchyme" patented technology

Tooth tissues include the pulp mesenchyme that forms the dentin and an epithelium that is responsible for enamel formation. Cells from these tissues were obtained from porcine third molars and were seeded onto a biodegradable scaffold composed of a polyglycolic acid—polylactic acid copolymer. Cell polymer constructs were then surgically implanted into the omentum of athymic nude rats so that the constructs would have a blood supply and these tissues were allowed to develop inside the rats. Infrequently, columnar epithelial cells were observed as a single layer on the outside of the dentin-like matrix similar to the actual arrangement of ameloblasts over dentin during early tooth development. Developing tooth tissues derived from such cell polymer constructs could eventually be surgically implanted into the gum of an edentulous recipient where the construct would receive a blood supply and develop to maturity, providing the recipient with a biological tooth replacement.

The present invention relates to a method for isolating stem / progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem / progenitor cells from the tissue cultures. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes. In one embodiment, the invention relates to the isolation and cultivation of stem cells such as epithelial and / or mesenchymal stem / progenitor cells under conditions allowing the cells to undergo mitotic expansion. Furthermore, the invention is directed to a method for the differentiation of the isolated stem / progenitor cells into epithelial and / or mesenchymal cells.

It is intended to provide a method of forming pancreatic β cells from mesenchymal cells characterized by comprising using mammal-origin mesenchymal cells as starting cells, culturing these cells in the presence of, for example, a pancreatic β cell-forming agent, and selecting and separating the thus obtained pancreatic βcells with the use of a gene expressed specifically in such cells as a selection marker; a remedy for glucose intolerance which comprises pancreatic β cells obtained by the above method as the active ingredient; a pancreatic β cell-forming agent such as a cytokine to be used in the above method; a method of screening a candidate compound promoting the formation of pancreatic β cells from mesenchymal cells; and a pancreatic β cell formation promoter obtained by this screening method.

The invention discloses a stem cell culture medium, an application of the stem cell culture medium and a stem cell cultivation method. Blood serum does not exist in the stem cell culture medium. The stem cell culture medium comprises amino acid, vitamin, salt, lipoid, cytokines and egg white polypeptide. The stem cell culture medium is suitable for fast cultivating stem cells which are tissue sources of human and mammal, and comprises but not is limited by fat mesenchyme stem cells, mesenchymal stem cells and umbilical cord blood stem cells. The culture medium enables increasing speed of the cells to be improved by 3-5 times, and differential potentials of the cells can not be affected. Compared with an ordinary stem cell culture medium, stem cells from different sources can be fast expanded, passage number is prolonged, and proficiency properties of the stem cells can be well kept.

The invention discloses a human placenta, umbilical cord mesenchyme stem cell bank and its making method. The method includes the following steps: the first is taking human placenta, umbilical cord to test; smashing after cleaning by phosphate buffer; adding phosphate buffer to dilute; the second is adding collagenase to digest; the third is adding phosphate buffer; the fourth is adding trypsinization; the fifth is mixing the cell from the second and fourth, centrifuging, removing supernatant, cleaning by the phosphate buffer, centrifuging, and removing supernatant; the mesenchyme stem cell are gained; the sixth is freezing them in liquid nitrogen; saving by ABO / Rh subtype and HLA subtype; setting recallable cell information file. The invention is newborn storage placenta and umbilical cord mesenchyme stem cell. It can offer mesenchyme stem cell to treat the disease for personal, family and others.

The invention discloses a preservation solution for mesenchymal stem cells and application thereof. The cell preservation solution contains human albumin and heparin as the main components, and other auxiliary reagents such as human cytokine, phosphate ion, metal ions or monosaccharide are contained in a buffer solution for preserving human mesenchymal stem cells. The preservation solution can keep high survival rate of human mesenchymal stem cells in transportation process, reduce adhesion between cells and between the cell and the inner wall of a container, and reduce the possible occurrence of cell mass embolism in blood vessel while clinically infusing human mesenchymal stem cells. The mesenchymal stem cells can be maintained in a state of single-cell suspension at an environment temperature of 4 to 15 DEG C for 24 h, thus greatly enlarging the clinic application range of the human mesenchymal stem cells. The components used in the solution accord with the clinic application, and can meet the requirement for clinic use of the human mesenchymal stem cells.

The invention provides icariin application in inducing stem cell in vitro orientation differentiates to several single type cells. The stem cell said includes embryonic stem cell, nerve stem cell and marrow mesenchyme stem cell. The single type cell includes nerve cell, bone cell, islet cells and endothelial cell. This invention also relates to application of the single type cell in preparing medicine of stem cell transplant curing nerve degenerative diseases, and its application in preparing cell differentiation agent that used to repair recovery injured nerve tissue, and its application in high efficiency drug effect screening model rebuilding and initial screening and estimating by using the model. The new applications of the icariin is extended in this invention, the fact of icariin contains pharmacy activity clarified, so it provides material basis for Chinese traditional medicine prevention and cure effect. The clarifying of drug effect mechanism provides reference for new medicine Chinese metical modern development with self-owned intellectual property right.

The present invention provides isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), which simultaneously express a plurality of genes that are markers for multiple cell lineages, wherein the multiple cell lineages comprise at least four different mesenchymal cell lineages (e.g., adipocyte, osteoblast, fibroblast, and muscle cell) and wherein each of the markers is specific for a single cell lineage. The present invention also method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.

The present invention relates to biomedicine technology, and is especially technological process of inducing and differentiating hemopoietic stem / ancestral cell of different sources into mature red blood cell by means of the support of stroma cell in a serum-free culture system. By means of the common culturing of stroma cell originated from embryo liver or mesenchyme stem cell originated from embryo marrow and erythron ancestral cell in different extracorporeal induction stages, the present invention realizes complete denucleation of erythrocyte to create erythrocyte with complete function. The present invention makes it possible to provide great amount of general or rare hematypic erythrocyte products for medical application.

The present invention is separating and culturing process of human amnion mesenchyme stem cell and its medical composition. The separating and culturing process includes digesting human amnion successively with trypsin, collagenase and deoxyribonuclease, and filtering to prepare single cell suspension; culturing in DMEM / F12 culture medium with VDMEM and VF12 in the equal ratio and containing ox embryo blood serum in 10-20 vol% and basic fibroblast growth factor of ultimate concentration 10-20 ng / ml inside a culture box at 37 deg.c, saturated humidity and CO2 in 5 vol%; and replacing liquid and culture passage to proliferate and purify human amnion mesenchyme stem cell. The process has wide material source no ethnic limitation and wide application foreground. The medical composition may be used in various kinds of treatment.

The invention discloses a method and application for inducing human umbilical cord mesenchyme stem cells to be differentiated into testicular interstitial cells. The method comprises the following step of culturing human umbilical cord mesenchyme stem cells of patients suffering from adenovirus and carrying mice steroidogenic factor-1 genes in a DMEM-F12 culture solution containing 0.3-3ng / ml of luteinizing hormone, 200-800mu M of dibutyryl cyclic adenosine monophosphate, 5*10<-6>-5*10<-4>M of all-trans retinoic acid (ATRA), 10mU / ml of human chorionic gonadotropin and 2.4uM of adrenocorticotrophic hormone for a week. Induced by the method in the invention, the human umbilical cord mesenchyme stem cells can be differentiated into testicular interstitial cells in vitro and provides important sources of cells for treating testosterone shortage by the cell replacing method or the genetic method.

The invention provides a laser-induced thermotherapy device and system based on magnetic resonance guidance. The device comprises a work station, laser ablation equipment and a minimally invasive operation optical fiber module; the work station is used for generating an operation plan according to the pre-operation focus digital image of a patient, sending the operation plan to the laser ablationequipment, generating a real-time temperature image of the focus region by using the magnetic resonance temperature imaging technology in the operation, and controlling the laser power and the coolingpower in real time through the temperature numerical values of the focus and the peripheral health tissue; the laser ablation equipment is used for producing and regulating the laser, driving and controlling the circulation of the cooling mesenchyme; the minimally invasive operation optical fiber module performs precise conformal ablation on the regular or irregular tumor in the disease treatmentby using the laser and the cooling mesenchyme and cools the operation optical fiber module and the peripheral tissue. The regular or irregular tumor can be effectively ablated, and the ablation boundary can be real-time adjusted in the operation through the nuclear magnetism temperature imaging, thereby achieving the conformal ablation aim.

The invention relates to an improved mesenchyme stem cell protection solution as well as application and a preparation method thereof. The protection solution can effectively prolong the activity remaining time of mesenchyme stem cells, reduces preparation cost, and has the advantages of wide raw material source, simple preparation, safe and reliable direct clinical application; and after the mesenchyme stem cells are preserved for 48 hours in the protection solution, the cell activity is still above 90 percent, the cell morphology is normal, and the multiplication capacity and mesenchyme stem cell phenotype characteristics are not influenced.

The invention provides a method for reshaping and beautifying by using tissue engineering fat regeneration technology, which is applicable to plastic surgery and reshaping and beautifying and belongs to the field of tissue engineering. The method comprises the following technical routes: directly extracting mesenchyme matrix cells with multiple differentiation capabilities from fatty tissues of a patient, culturing and propagating the mesenchyme matrix cells in vitro, wrapping a specific amount of cells and other necessary components in a hydrogel stent material, and implanting the hydrogel stent material into the corresponding part in the body of the patient. The cells are grown into fatty tissues along with degradation and absorption of the stent material so as to perform regenerative repair on the soft tissue defect of the patient. The method has the advantages that the cells of the patient do not bring immunological rejection to the patient, and the regenerative repair effect is safe, natural and durable because the used hydrogel stent material is finally degraded and absorbed in the body of the patient.

The present invention relates to histoengineering bone comprising porous histoengineering bone rack material, composite heterogene seed cell and / or bioactive factor. The histoengineering bone is constituted through treating heterogene cancellous bone via hypotonic solution and ultrasonic cleaning, complete or partial decalcification, defatting, antigen eliminating, etc to obtain high porosity rack material; compounding mesenchyme stem cell, osteoblast and other seed cell and / or bone morphogonetic protein of the heterogene, vascular endothelial growth factor, antibacterial medicine and other bioactive factors; and applying human serum or no serum culture medium following culturing in ox serum culture medium to reduce heterologous serum residue so as to constitute histoengineering bone product ultimately. The histoengineering bone has high performance and is used as bone repairing material clinically.

The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and / or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

The invention relates to a preparation method of tissue engineering skin containing appendant organs. In the invention, the preparation method comprises the following steps of: inoculating amniotic mesenchyme stem cells, amniotic mesenchyme stem cells induced to the directions of hair papillae, amniotic epithelial cells and amniotic epithelial cells induced to the directions of the epithelia of the sweat gland into a gel solution, then inoculating the amniotic epithelial cells and the amniotic epithelial cells induced by keratinocyte in a warp direction on the surface of a structure of the hair follicle and the sweat gland after culturing by a dermal layer by induced culture forming the structure of the hair follicle and the sweat gland, and obtaining the tissue engineering skin with the structure of the hair follicle and the sweat gland after culturing. The skin has elasticity, toughness, vigorous cellular metabolism, strong multiplication capacity, sufficient secretion of extracellular matrices, tight linkage of the cuticular layer, the inophragma and the cells of the dermal layer and little possibility of falling off, enhances the success rate of transplantation, can promote the healing of a wound surface, enhances the effects of restoration and replacement and has the function of regulating the immunological rejection of a receptor; by the contained structure of the hair follicle and the sweat gland, the function of the skin is more complete; the adopted amniotic tissues are postpartum wastes and have extensive source, strong cell multiplication capability and multiplepassage frequency; and the invention is beneficial to the mass production of seed cells and lowers the industrialization cost.

The invention discloses a placenta stem cell bank construction method and a placenta tissue resuscitation method, and relates to placenta stem cell bank construction methods. The placenta stem cell bank construction method comprises the following steps: after non-bacterial cleaning treatment to placenta tissues of at least three parts, the steps of tissue peeling, further sterilizing, shearing to be thin, protecting using a refrigerant, programmed freezing, cryogenic temperature temporary storage, long term storage with nitrogen canisters, and the like are carried out, and the placenta tissue with biological activities can be preserved for a long term. The placenta tissue preserved through the method can be used for the construction of a stem cell bank, resuscitation, enzymic digestion, cultivation, expansion, quality inspection and the like are performed after selective tissue part resuscitation according to required cell types, so as to obtain placenta amniotic membrance epithelial cells, placenta amniotic membrance mesenchyme, placenta chorion mesenchymal stem cell, placenta decidua serotina mesenchymal stem cells and the like. The method provided by the invention has the advantages that operation steps are simplified, manual intervention errors are reduced, the efficiency is improved, more stem cell resources are preserved, and a basis is provided for further personalized stem cell customization.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal al development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

A method for preparing chondroblast of bone marrow mesogalia stem cell with three dimensional cultivation and induction includes steps of placing bone marrow mesogalia stem cell into suspending culture device preset with culture medium and microcarrier for suspending cultivation; cloning abovesaid stem cells with agitation, adding induction culture medium of chondroblast in culture meidum containing harvested cytodex3 microcrrier and abovesaid stem cells gromn on it; and carrying out induction for chondroblast assembly from abovesaid stem cells.

The present invention relates to methods of generating and expanding hitman embryonic stem eel! derived mesenchymal-like stem / siromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (ES) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (RA) into the permeable microcapsule system. This application also discloses a micro-encapsulation system for immobilizing mesenchymal stromal cells (MSCs) while sustaining the molecular communication. Thus, the invention provides the use of encapsulated mesenchymal stromal cells in the cellular transplantation therapies. Moreover, the invention provides methods for delivery of encapsulated MSCs into the central nervous system and therapies derived therefrom, such as, the treatment of spinal cord injury (SCI) and other inflammatory conditions.

The invention provides a sub-totipotent stem cell of a human placenta. The sub-totipotent stem cell of the human placenta is derived from stripped human placenta amnion, aiming at the characteristics of cells contained by an epithelial layer and a mesenchyme layer of the amnion, a step-by-step separation method is adopted, pollution of the sub-totipotent stem cell of the placenta by the mesenchyme layer of the amnion is reduced to the greatest extent, and the stemness of the sub-totipotent stem cell of the human placenta is improved effectively. The method has the characteristics of low cost, broad application prospect and capacity of supplying a large quantity of stem cell resources to clinic and research. The invention further provides a method for preparing the sub-totipotent stem cell of the human placenta from the human placenta amnion and constructing a stem cell bank.

The present invention discloses a method for cultivating the mesenchymal stem cells from the oral tissue. A dental pulp or gingival mucosa sample is prepared, dental pulp mesenchymal stem cells are abstracted from the dental pulp tissue of the tooth or gingival mucosa mesenchymal stem cells are abstracted from a gingival mucosa tissue, then, the cells are cultivated, the cells present the kenel of the dental pulp mesenchymal stem cells or kenel of the gingival mucosa mesenchymal stem cells, and the next cultivation and the preservation are operated. The dental pulp mesenchymal stem cells and the gingival mucosa mesenchymal stem cells abstracted through the method of the present invention have the abilities of clustering, differentiating into the substance of bone, differentiating into fat, and differentiating into nerve. The method of the present invention reduces the pollution rate, and leads the mesenchymal stem cells to be easily cultivated and preserved.

The invention discloses an umbilical cord preserving fluid for temporary preservation of umbilical cord after collection before separation. The umbilical cord preserving fluid comprises the following main components: sodium chloride, glucose, human serum albumin, potassium chloride and anhydrous calcium chloride, as well as auxiliary components: cefoperazone sodium and phenol red, wherein the main components have the effects on maintaining osmotic equilibrium of inner cells of the umbilical cord tissue, keeping the umbilical cord in a wet state and providing nutrient content for a short period of time; and the auxiliary components have the effects on preventing probable pollution and prompting happened pollution. The preserving fluid can be used for preserving the activity of mesenchyme stem cells in the umbilical cord, the umbilical cord can be effectively preserved at 2-10 DEG C for at least 72 hours, the activity of the separated mesenchyme stem cells is minimally influenced by time, the time limit from collection to preparation of the umbilical cord is greatly reduced, and all the used components meet a clinical use standard and are capable of effectively reducing the pollution probability.

The invention discloses a multipotential stem cell-derived mesoderm pedigree mesenchymal stem cell and an induced differentiation method thereof. The multipotential stem cell-derived mesoderm pedigreemesenchymal stem cell is prepared by the following steps: performing in-vitro adherent culture on multipotential stem cells and maintaining the undifferentiation state of the multipotential stem cells; preparing unicellular or cell mass suspension from the cells, inoculating to a culture dish coated with matrix glue, and performing cultivation by using the multipotential stem cell culture liquid;after the cells adhere to the wall, adding GSK-3 pathway inhibitor combination into the culture liquid; after growing for 2 to 10 days, obtaining a mesoderm progenitor population; and after subculturing continuously for 2 to 6 times by using mesenchymal stem cell culture liquid, detecting the cell phenotype of mesenchyme. The defects that the human-derived mesenchymal stem cells and the mesenchymal stem cells derived from other non-finite induced way multipotential stem cells have heterogeneity and hybridity are overcome, and the obtained mesoderm pedigree mesenchymal stem cells have higher proliferation capability and immunoregulation capability; and the standardized induced differentiation process can guarantee that the cell populations obtained from different batches have high consistency.

The invention discloses four cell types which have wide heteroplastic transplantation application prospect and can be effectively induced into induced pluripotent stem (iPS) cells. The origins of three cell types are placental tissue, namely amnion mesenchymal cell, chorion mesenchymal cell and umbilical cord mesenchymal cell; and the origin of the other one is amniotic fluid cell. Besides, the invention also discloses an induction reprogramming method for producing cells capable of producing induced pluripotent stem (iPS) cells by efficient induction, including the following steps: cDNA containing pluripotent stem cell factor is respectively introduced into the four primary culture cells; the four primary cells in which cDNA is introduced are respectively cultured on appropriate culture mediums, primary iPS is obtained and then quality of iPS is optimized on appropriate culture mediums, and cloning of pluripotent stem cell can be primarily evaluated. In the invention, three mesenchymal cells of placenta origin and amniotic fluid cell all can be induced into iPS, wherein the chorion mesenchymal cell is compared with fibroblast, efficiency of induction reprogramming is improved by over 100 times, efficiency is about 2.3%, and the efficiency is slightly higher than that of horny cell; and a means which is more effective and more pertinent is provided for building disease model, screening drug and controlling oriented differentiation.